AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma

This article was originally published here

The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs. In 2017, AstraZeneca

The post AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply